AbbVie (NYSE:ABBV) Trading 2% Higher After Analyst Upgrade

AbbVie Inc. (NYSE:ABBV) shares traded up 2% on Friday after Morgan Stanley raised their price target on the stock from $269.00 to $270.00. Morgan Stanley currently has an overweight rating on the stock. AbbVie traded as high as $225.82 and last traded at $223.50. 6,049,138 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 7,671,626 shares. The stock had previously closed at $219.02.

Several other research firms also recently weighed in on ABBV. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Guggenheim lifted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Piper Sandler restated an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. Finally, Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.00.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

Institutional Investors Weigh In On AbbVie

A number of institutional investors have recently added to or reduced their stakes in the company. Chelsea Counsel Co. acquired a new position in AbbVie in the 3rd quarter worth $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter worth about $31,000. Legacy Wealth Managment LLC ID lifted its stake in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

The business has a fifty day moving average of $223.74 and a 200 day moving average of $219.41. The stock has a market cap of $395.01 billion, a PE ratio of 94.70, a P/E/G ratio of 0.89 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.